Menu

Medicine comparison

Wegovy, Ozempic, Mounjaro and Zepbound in Canada

Two medicines, four product names. What each is authorized for in Canada, what public plans list, and what the trials that compared them directly found.

Wegovy and Ozempic are both semaglutide. Mounjaro and Zepbound are both tirzepatide. Within each pair the medicine is the same; the products differ in what they are authorized for in Canada, in their dose range and presentation, and in how public plans treat them. The table below shows each product from its own Health Canada record.

Nothing on this page says which product suits anyone, and nothing here is a dose. That is a decision for a prescriber who knows the person's history.

The four products side by side

Four products, from each product's DPD record and monograph
ProductMedicineCompanyWhat it is authorized for in CanadaDPD statusStatus date
WegovysemaglutideNovo Nordisk Canada IncChronic weight management: adults with BMI 30 or more, or 27 or more with a weight-related condition; ages 12 to under 18 with BMI at or above the 95th percentile, body weight above 60 kg and inadequate response to diet and activity. Adult reduction of non-fatal myocardial infarction risk with established cardiovascular disease and BMI 27 or more. Adult non-cirrhotic MASH with fibrosis F2 to F3 under conditional authorization (NOC/c). R21-C434 R21-C435 R21-C449 R21-C450 A-C03Marketed (multidose pens); Approved, not marketed (single-dose pens)Multidose pens marketed 2024-03-28 to 2026-08-27; single-dose pens approved 2021-11-23
OzempicsemaglutideNovo Nordisk Canada IncAdults: type 2 diabetes glycemic control; reduction of major adverse cardiovascular events with established cardiovascular disease and/or chronic kidney disease; renal and cardiovascular risk reduction with type 2 diabetes plus chronic kidney disease. Not a weight-management indication. R21-C459 A-C04Marketed (02471469, 02540258); Dormant (02471477); Approved, not marketed (02523930, 02562618, 02562626)02471469 marketed 2018-02-22; 02540258 marketed 2023-12-22; 02471477 dormant 2026-07-24
ZepboundtirzepatideEli Lilly Canada IncAdults: chronic weight management with BMI 30 or more, or 27 to under 30 with a weight-related condition; moderate to severe obstructive sleep apnea with obesity (BMI 30 or more). Alongside reduced calories and increased activity. R21-C461 A-C07Marketed2026-02-12 (7.5 mg 2026-02-16)
Mounjaro and Mounjaro KwikPentirzepatideEli Lilly Canada IncType 2 diabetes glycemic control in adults and in ages 10 to under 18 with specified combinations. Not a weight-management indication. R21-C460 A-C06Marketed (vials and KwikPen); Approved, not marketed (single-dose pens)Vials marketed 2023-10-23; KwikPen marketed 2024-12-10; single-dose pens approved 2022-11-24

Generic semaglutide products and Sevmia, the generic authorized for weight management, are on the semaglutide page, with every presentation and status.

Which ones do public plans cover?

Public plans list injectable semaglutide (Ozempic and the generics) for type 2 diabetes, with criteria. No province reviewed lists Wegovy, Zepbound or any other product for chronic weight management, apart from Imcivree for two rare genetic conditions. The coverage page has the answer for each province and territory, with dates; private plans differ and are not covered here.

What the trials that compared them found

Two trials compared tirzepatide with semaglutide directly, and they answer different questions. SURPASS-2 used semaglutide 1 mg, a diabetes dose, in people with type 2 diabetes, with HbA1c as the main outcome. SURMOUNT-5 used the highest dose each person could tolerate of each medicine in people without type 2 diabetes, with weight as the main outcome, and found -20.2% with tirzepatide and -13.7% with semaglutide at 72 weeks. Both trials were open-label, and SURMOUNT-5 was funded by the maker of tirzepatide. One trial in one population is not a general ranking of the two medicines, and SURMOUNT-5 did not measure heart events.

From the summary on Tirzepatide studies explained, reviewed by two pharmacists registered in British Columbia, 2026-09-23.

The two trials are explained in full on their own pages: SURMOUNT-5 and SURPASS-2. For everything else known about each medicine, see the semaglutide studies and the tirzepatide studies.

Where to go next

Sources for this page

Every claim ID below is a row in the evidence ledger. The source date is the date the source itself carries; the access date is when the researcher opened it. A claim with several rows is one claim with several sources, not several confirmations.

Source records for every claim cited on this page
ClaimWhat the source saysSourceSource dateAccessedLabel
R21-C434Weight management: adults BMI ≥30, or ≥27 plus comorbidity; ages 12 to <18 with BMI ≥95th percentile, >60 kg and inadequate diet/activity response. Adult nonfatal-MI reduction: established CVD/BMI ≥27. Adult noncirrhotic MASH, fibrosis F2, F3, is conditional.pdf.hres.ca/dpd_pm/00082777.PDF2025-12-102026-09-17regulator-confirmed
R21-C435Single-use pens: 0.25/0.5/1/1.7/2.4 mg. FlexTouch: 1/2/4/6.8/9.6 mg per pen; delivers 0.25/0.5/1/1.7/2.4 mg. MASH remains NOC/c; recent indication change 2025-10.pdf.hres.ca/dpd_pm/00082777.PDF2025-12-102026-09-17regulator-confirmed
R21-C449Wegovy remains on the current NOC/c list without a conditions-met notation. The list gives issuance as 2025-12-11, one day later than the NOC and PM.canada.ca/en/health-canada/services/drugs-health-products...Updated 2026-08-182026-09-17regulator-confirmed
R21-C450Qualifying notice requires the final ESSENCE confirmatory report, expected submission in 2029.canada.ca/en/health-canada/services/drugs-health-products...Page dated 2025-12-192026-09-17regulator-confirmed
A-C03 source 1 of 2Wegovy Canadian weight-management, nonfatal MI and conditional MASH indicationsnovonordisk.ca/content/dam/nncorp/ca/en/products/wegovy/p...2025-12-102026-09-16regulator-confirmed
A-C03 source 2 of 2Selected Wegovy FlexTouch DINs marketed; presentation-level status varieshealth-products.canada.ca/dpd-bdpp/search-fast-recherche-...Live indexed record2026-09-16regulator-confirmed
R21-C459Adults: type 2 diabetes glycemic control; MACE reduction with established CVD and/or CKD; renal/CV risk reduction with type 2 diabetes plus CKD. No pediatric indication. These are not weight-management indications.pdf.hres.ca/dpd_pm/00085314.PDF2026-07-132026-09-17regulator-confirmed
A-C04 source 1 of 2Ozempic adult T2D and T2D/CKD indications; no pediatric indicationpdf.hres.ca/dpd_pm/00084255.PDF2026-04-142026-09-16regulator-confirmed
A-C04 source 2 of 2Ozempic DIN 02471469 Marketed and 02471477 Dormanthealth-products.canada.ca/dpd-bdpp/search-fast-recherche-...Live indexed record2026-09-16regulator-confirmed
R21-C461Adults: chronic weight management (BMI ≥30 or 27 to <30 plus comorbidity) and moderate/severe OSA with obesity (BMI ≥30), alongside reduced calories/activity. OSA indication change 2026-06; no pediatric indication. KwikPen strengths 2.5/5/7.5/10/12.5/15 mg per 0.6 mL.pdf.hres.ca/dpd_pm/00084997.PDF2026-06-112026-09-17regulator-confirmed
A-C07 source 1 of 2Zepbound label includes adult chronic weight management and moderate-to-severe OSA with obesitypi.lilly.com/ca/zepbound-ca-pm.pdf2026-06-112026-09-16regulator-confirmed
A-C07 source 2 of 2Zepbound Canadian availability announced July 2025lilly.com/en-ca/news/press-releases/zepbound-kwikpen-appr...2025-07-092026-09-16company self-report
R21-C460Type 2 diabetes glycemic control: adults and ages 10 to <18 with specified combinations. Pediatric indication change recorded 2026-06. Presentations: single-dose vial/pen 2.5 to 15 mg per 0.5 mL; KwikPen 2.5 to 15 mg per 0.6 mL delivered, four doses.pdf.hres.ca/dpd_pm/00085122.PDF2026-06-232026-09-17regulator-confirmed
A-C06 source 1 of 2Mounjaro current label includes T2D age >=10 with metformin and/or basal insulinpi.lilly.com/ca/mounjaro-ca-pm.pdf2026-06-232026-09-16regulator-confirmed
A-C06 source 2 of 2Mounjaro vial 02541106 Marketed; selected single-use pen remains Approvedhealth-products.canada.ca/dpd-bdpp/info?code=102977&lang=engVial marketing 2023-10-23; current indexed status2026-09-16regulator-confirmed